We are pleased to share an exciting update regarding PhorMed's journey towards a 'Go-Public' transaction. Our CEO recently sent an email to current investors detailing our plans to embark on this significant transition. Here's a brief overview of what was shared:

• Go-Public Transaction: PhorMed has begun taking steps towards conducting a 'GO-PUBLIC' transaction. We will work closely with the broker-dealer and market-maker, Glendale Securities, throughout this process. 
• Crowdfunding Continues: We will continue our crowdfunding efforts. Our aim is to raise up to $5 million to support a seamless transition and further fuel our mission to tackle unmet medical needs head-on, addressing root causes rather than just symptoms. 
• Valuation: Our goal would be to have a valuation of at least $ 70 million in a go-public transaction, up from our current valuation of $52.6 million. At that new valuation, the share price would be at least $1.33, which would be a 33% increase from today's share price of  $1.00 per share.
• Special Offer: PhorMed is offering shares at a discount. Act fast to take advantage of this limited-time offer of $0.90 per share.

We would greatly appreciate it if you could share this update with your friends and family. Your support and involvement are invaluable to us as we strive to bring hope and a brighter future to patients battling deadly diseases. Follow us by clicking the ❤️ at the top or right of the campaign page.

Thank you for your support. Together, we can make a meaningful difference.

All the best,

The PhorMed Team